CCL17 and neoplasm: Once activated, TAMs secrete CCL17, a chemokine that further fuels the invasive and metastatic potential of pituitary tumors, which engages the CCL17/C-C chemokine receptor type 4 (CCR4)/mTORC1 axis, thereby enhancing the tumor’s capacity for invasion and metastasis.